Skip to main content
Premium Trial:

Request an Annual Quote

Invitrogen Licenses Amplification Patents to Qiagen and Others

NEW YORK (GenomeWeb News) – Invitrogen today said that it had non-exclusively licensed its patents covering the random prime amplification of nucleic acids to Qiagen, New England Biolabs, and Kirkegaard & Perry Laboratories.
 
The patents cover methods and kits used for “substantially” amplifying nucleic acids, Invitrogen said. The technology is used in common lab techniques, such as random prime labeling reactions, first-strand cDNA synthesis, and whole genome amplification.
 
Financial terms of the licenses were not disclosed.

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.